Jeffrey Bruckel, MD
Cardiovascular Disease · Rochester, NYNPI 1912226861
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,000 of the $4,532 with a category attached, or 66.2%. Asahi Intecc USA, Inc. accounts for 66.2% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $3,018 and has fallen 88.6% since, to $345 in 2022.
Across 16 payments — averaging $283.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Asahi Intecc USA, Inc.$3K
- Medtronic$1K
- Boston Scientific$310
- Edwards Lifesciences$35
- CSL Behring$23
- Philips North America LLC$18
Across 41 payments — averaging $2390.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inari Medical, Inc.$98K
What the payments were for
- Consulting fees$3,00066%
- Travel & lodging$1,00422%
- Food & beverage$52812%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Asahi Intecc USA, Inc. | 2 | $3,000 |
| Medtronic | 8 | $1,146 |
| Boston Scientific | 3 | $310 |
| Edwards Lifesciences | 1 | $35 |
| CSL Behring | 1 | $23 |
| Philips North America LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ASAHI PTCA Guide Wire$3,000
- COUGAR$869
- GENERAL - STRUCTURAL HEART$172
- GENERAL - THERAPIES$121
How this compares
$4,532 in reported general payments places this provider in the 70th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 59 | $67,845 |
| JardianceEmpagliflozin | 17 | $25,669 |
| XareltoRivaroxaban | 13 | $15,959 |
| BrilintaTicagrelor | 14 | $12,040 |
| EntrestoSacubitril/Valsartan | 14 | $10,699 |
| Rosuvastatin Calcium | 91 | $2,231 |
| Atorvastatin Calcium | 98 | $1,787 |
| Eplerenone | 26 | $1,743 |
| Metoprolol Succinate | 105 | $1,675 |
| Valsartan | 46 | $1,472 |
| Ezetimibe | 26 | $871 |
| Amlodipine Besylate | 61 | $441 |
| ClopidogrelClopidogrel Bisulfate | 30 | $441 |
| Losartan Potassium | 23 | $382 |
| Torsemide | 27 | $369 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Rochester
- James EichelbergerRochester$332K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.